Roche aims to 'underwhelm' on SMA drug price to challenge rivals


14 January 2020 - Swiss drug maker Roche plans to price its oral spinal muscular atrophy drug risdiplam aggressively to challenge two of the world’s most expensive medicines, Biogen’s Spinraza and Novartis’s gene therapy Zolgensma.

Spinraza’s list price is $750,000 in the first year, and $375,000 thereafter, while Novartis’s gene therapy for the genetic muscle wasting disease lists at $2.1 million, making it the drug industry’s most expensive one-time treatment.

Third-to-market risdiplam is due for a U.S. FDA decision by May 24.

Read Reuters article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Pricing , Gene therapy